



COPY OF PAPERS
ORIGINALLY FILED

GP 1647

Docket No.: PF-0510-1 CON

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 27, 2002

By:

Debbie Ellis

Printed:

Debbie Ellis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Lal et al.

SEP 10 2002

Title: HUMAN NEUROSECRETORY PROTEINS

TECH CENTER 1600/2900

Serial No.: 10/077,040

Filing Date:

February 14, 2002

Examiner: To Be Assigned

Group Art Unit:

1647

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/062,601, filed April 17, 1998, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 27 August 2002

Cathleen M. Rocco

Cathleen M. Rocco

Reg. No. 46,172

Direct Dial Telephone: (650) 845-4587

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PF-0510-1 CON		10/077,040	
LIST OF REFERENCES CITED BY APPLICANTS				Applicant(s)			
(Use several sheets if necessary)				Lal et al.			
				Filing Date		Group	
				February 14, 2002		1647	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,672,479	9/30/97	Johnson et al.			RECEIVED SEP 10 2002
	2	5,876,931	3/2/99	Holden			
Foreign Patent Documents							
TECH CENTER 1600/2900							
		Document	Date	Country	Class	Subclass	Yes No
	3	WO 99/40189	12 Aug.				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	4	Rosa, P., and H.H. Gerdes, "The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors," <u>J. Endocrinol. Invest.</u> , 17:207-225 (1994)					
	5	Ottiger, H.P. et al., "1B1075: A Brain- and Pituitary-Specific mRNA that Encodes a Novel Chromogranin/Secretogranin-like Component of Intracellular Vesicles," <u>J. Neurosci.</u> , 10(9):3135-3147 (1990)					
	6	Dopazo, A. et al., "Primary Structure of Mouse Secretogranin III and Its Absence from Deficient Mice," <u>J. Mol. Neurosci.</u> , 4(4):225-233 (1993)					
	7	Kingsley, D. et al. "Genetic ablation of a mouse gene expressed specifically in brain," <u>The EMBO J.</u> , 9(2):395-399 (1990)					
	8	Holthuis, J. et al., "Secretogranin III Is a Sulfated Protein Undergoing Proteolytic Processing in the Regulated Secretory Pathway," <u>J. Biol. Chem.</u> , 271(30):17755-17760 (1996)					
	9	Hendy, G. et al., "REVIEW: Chromogranin A," <u>Clin. Invest. Med.</u> , 18(1):47-65 (1995)					
	10	Jensen, R. et al., "BRCA1 is secreted and exhibits properties of a granin," <u>Nat. Genet.</u> , 12:303-308 (1996)					
Examiner			Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							

COPIES OF PAPERS
ORIGINALLY FILED

SEP 09 2002
O I P E
PATENT & TRADEMARK OFFICE

RECEIVED
SEP 10 2002
TECH CENTER 1600/2900

COPIES OF PAPERS
ORIGINALLY FILED